NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News → Your Money is Not Safe (From American Alternative) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.48▼$16.7850-Day Range$27.45▼$32.2552-Week Range$25.99▼$35.82Volume12,378 shsAverage Volume6,668 shsMarket Capitalization$14.96 millionAssets Under Management$28.75 millionDividend Yield1.74%Net Expense Ratio0.79% Stock AnalysisStock AnalysisDividendHeadlinesHoldingsOwnershipRatingsShort InterestSocial MediaStock AnalysisDividendHeadlinesHoldingsOwnershipRatingsShort InterestSocial Media Get Range Cancer Therapeutics ETF alerts: Email Address About Range Cancer Therapeutics ETFThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here CNCR ETF News HeadlinesMarch 15, 2024 | msn.comLarge-scale study explores genetic link between colorectal cancer and meat intakeMarch 11, 2024 | markets.businessinsider.comMicrobix Unveils Test Controls for Head and Neck CancerMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 3, 2024 | nasdaq.comThe Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKBFebruary 22, 2024 | msn.comFDA approval of cancer treatment provides new weapon against tumorsFebruary 21, 2024 | msn.comA watershed moment for cancer therapies has arrivedFebruary 5, 2024 | nz.finance.yahoo.comETF S.S.-LONCAR CAN.I.ETF (E18B.BE)January 24, 2024 | msn.comWhy Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?March 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. January 4, 2024 | markets.businessinsider.comTScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent ProgressSee More Headlines Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings80 Fund Statistics Assets Under Management$23.57 million Average Daily Volume$73,498.30 Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest68,300 shs Miscellaneous Outstanding Shares900,000Beta0.90 Creation Unit50,000 Creation Fee$150.00 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.57%0.54%0.48%0.51%Other Expenses0.00%0.40%0.54%0.32%0.58%Total Expense0.79%0.72%0.70%0.57%0.70%Fee Waiver0.00%-0.53%-0.54%-0.20%-0.56%Net Expense0.79%0.61%0.60%0.54%0.58% Range Cancer Therapeutics ETF (CNCR) Holdings & ExposureTop 10 CNCR HoldingsUS DOLLARSHolding Weight: 6.35%Caribou Biosciences(NASDAQ:CRBU)Holding Weight: 1.77%HUTCHMED(NASDAQ:HCM)Holding Weight: 1.65%Recursion Pharmaceuticals(NASDAQ:RXRX)Holding Weight: 1.58%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 1.58%EQRx(NASDAQ:EQRX)Holding Weight: 1.48%Apollomics(NASDAQ:APLM)Holding Weight: 1.45%VectivBio(NASDAQ:VECT)Holding Weight: 1.45%Exscientia(NASDAQ:EXAI)Holding Weight: 1.43%Immunocore(NASDAQ:IMCR)Holding Weight: 1.42%CNCR Sector ExposureCNCR Industry ExposureFull Holdings Details Similar ETFsFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHHorizon Kinetics Medical ETFNASDAQ:MEDXInvesco Nasdaq Biotechnology ETFNASDAQ:IBBQJPMorgan Healthcare Leaders ETFNASDAQ:JDOCProShares UltraShort Nasdaq BiotechnologyNASDAQ:BISInstitutional OwnershipOLD Mission Capital LLCBought 16,319 shares on 2/15/2024Ownership: 1.813%View All Institutional Transactions CNCR ETF - Frequently Asked Questions Are investors shorting Range Cancer Therapeutics ETF? Range Cancer Therapeutics ETF saw a increase in short interest in March. As of March 15th, there was short interest totaling 68,300 shares, an increase of 73.4% from the February 29th total of 39,400 shares. Based on an average trading volume of 32,600 shares, the short-interest ratio is currently 2.1 days. View Range Cancer Therapeutics ETF's Short Interest. What does CNCR invest in? Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $28.75 million assets under management. What stocks does Range Cancer Therapeutics ETF hold? CNCR invests in 80 holdings. Some of the stocks in their portfolio include Caribou Biosciences (CRBU), HUTCHMED (HCM), Recursion Pharmaceuticals (RXRX), Revolution Medicines (RVMD), EQRx (EQRX), Apollomics (APLM), VectivBio (VECT), Exscientia (EXAI), Immunocore (IMCR) and Exelixis (EXEL). What is the management fee for Range Cancer Therapeutics ETF? Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%. What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX). Who are Range Cancer Therapeutics ETF's major shareholders? Range Cancer Therapeutics ETF's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include OLD Mission Capital LLC (1.81%). This page (NASDAQ:CNCR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.